ESC 365 - Cardiac troponin autoantibodies in breast cancer patients receiving adjuvant cardiotoxic chemotherapy: the PRADA study

Delegates Premium Access

Cardiac troponin autoantibodies in breast cancer patients receiving adjuvant cardiotoxic chemotherapy: the PRADA study

Session: Insights into anthracycline-induced cardiotoxicity and treatment perspectives

Topic: Research and New Technology

Speaker: Ms H. Junes (Turku, FI)

Event: ESC Cardio-Oncology 2025

Congress Presentation

Add to my library

About the speaker

Ms Helea Junes

Turku (Finland)

0 follower

9 more presentations in this session

Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3

Speaker: Doctor V. Quagliariello (Naples, IT)

Targeted cardiac inactivation of Guanylate binding protein 5 (GBP5) protects from cardiotoxicity after doxorubicin treatment

Speaker: Associate Professor L. Lehmann (Heidelberg, DE)

Cardioprotective effects of the flavonoid quercetin against doxorubicin-Induced cardiotoxicity in H9c2 cardiomyoblasts

Speaker: Doctor N. Chong (Nottingham, GB)

Exploring the cardioprotective efficacy of roflumilast as potential cAMP regulator against experimental epirubicin-induced myocardial injury: insights into oxidative stress and apoptosis.

Anthracycline exposure alters the response to future cardiac stress response driven by FOXK1

Speaker: Mr V. Sunder (Heidelberg, DE)

Access the full session

Insights into anthracycline-induced cardiotoxicity and treatment perspectives

Speakers: Ms H. Junes, Doctor V. Quagliariello, Associate Professor L. Lehmann, Doctor N. Chong, Mr V. Sunder

About the event

ESC Cardio-Oncology 2025

20 June - 21 June 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources